ERBB2 and gastric cancer: Firstly, a phase I study conducted by Shitara and colleagues reported promising levels of activity in 44 HER2-positive GC patients with advanced disease receiving T-Dxd at a dose of 5.4 or 6.4 mg/kg (NCT02564900) [36].